Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLG | P54098 | 1/20 | 0.47 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.45 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.45 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | DTYMK | P23919 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6229380 | 0.90 | POLG (0.46) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL6229367 | 0.90 | POLG (0.46) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL22327062 | 0.89 | POLG (0.44) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL13314154 | 0.88 | POLG (0.47) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL26068621 | 0.87 | POLG (0.42) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL8417580 | 0.87 | POLG (0.51) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL22327108 | 0.87 | POLG (0.51) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL10022245 | 0.87 | POLG (0.51) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL5664002 | 0.87 | POLG (0.51) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL5664015 | 0.87 | POLG (0.51) | POLGP2RY2P2RY4P2RY6POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4355757-A1 | NUCLEOSIDE-5 -OLIGOPHOSPHATES HAVING A CATIONICALLY-MODIFIED NUCLEOBASE | F. Hoffmann-La Roche AG (CH) | 2024-04-24 | — | — | EP | disclosed |
| WO-2022263489-A1 | NUCLEOSIDE-5 -OLIGOPHOSPHATES HAVING A CATIONICALLY-MODIFIED NUCLEOBASE | F. HOFFMANN-LA ROCHE AG (CH) | 2022-12-22 | — | — | WO | disclosed |